← Eichor
Condition: Advanced Clear Cell Renal Carcinoma Ccrcc Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Advanced Clear Cell Renal Carcinoma Ccrcc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works
Phase 1/Phase 2 · 11 location(s) · Regeneron Pharmaceuticals · NCT06413680A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
Phase 2 · 2 location(s) · Stephanie Berg · NCT07123090Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Car
Phase 3 · 134 location(s) · Arcus Biosciences, Inc. · NCT07011719GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Phase 1/Phase 2 · 12 location(s) · GI Innovation, Inc. · NCT04977453Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Phase 1 · 122 location(s) · Exelixis · NCT05176483Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Phase 1/Phase 2 · 5 location(s) · Oncorena AB · NCT05287945KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Phase 1 · 38 location(s) · Kura Oncology, Inc. · NCT06026410A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Phase 1 · 6 location(s) · Pliant Therapeutics, Inc. · NCT06270706A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Phase 1 · 22 location(s) · Incyte Corporation · NCT07195916Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05665361A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerabili
Phase 1/Phase 2 · 10 location(s) · ITM Oncologics GmbH · NCT05706129Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Ce
Phase 1 · 11 location(s) · Neomorph, Inc · NCT07300241Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
Phase 3 · 5 location(s) · Telix Pharmaceuticals (Innovations) Pty Limited · NCT07197580A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Expres
Phase 1 · 5 location(s) · Novelty Nobility, Inc. · NCT06805825A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal
Phase 2 · 2 location(s) · Brian Rini · NCT07188896A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Phase 1 · 9 location(s) · Bristol-Myers Squibb · NCT07195682
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.